2023

PromarkerD to be available in Chile in expanded deal with Omics Global Solutions

AGM Chairman’s Address and Investor Presentation

US Medicare confirms reimbursement price for PromarkerD

Proteomics International receives $1.85 million in R&D tax incentive

Investor Presentation – Non-deal Roadshow

Quarterly Activities Report September 2023 – Appendix 4C

Notice of Annual General Meeting 2023

Webinar and Q&A on PromarkerD US CMS price & TGA decision

PromarkerD US CMS price & TGA decision

Oseophageal cancer test presented

OxiDx technology secures Japan patent

Corporate Governance Statement and Appendix 4G

Annual Report to shareholders

Preliminary Final Report

Exercise of Options

Application for quotation of securities – PIQ

Proteomics presents at 17th Bioshares Biotech Summit

Quarterly Activities Report and Year Ahead

Promarker pipeline – Oesophageal cancer diagnostic test update

Proteomics International & Sonic Healthcare USA sign exclusive licence agreement to market PromarkerD in the US

New diagnostic blood test showcased at world’s premier endometriosis conference

PromarkerD is a potential diagnostic tool to demonstrate the benefits of canagliflozin in diabetic kidney disease

Quarterly update March 2023 – Appendix 4C

Clinical Advisory Board expanded to support PromarkerD USA and global rollout

Proteomics renews its ISO 13485 certification & ISO 17025 accreditation

Results of a novel blood test for Endometriosis were presented at international conference

US update: PromarkerD licensing negotiations

Distribution agreement for PromarkerD in Britain extended

Investor Presentation – Euroz Hartleys Healthcare Forum

Letter of intent with Sonic Healthcare USA extended

Quarterly Update December 2022 – Appendix 4C

Letter of intent with Sonic Healthcare USA extended

CPT PLA Reimbursement Code Approved in US for PromarkerD